GO:0035642 histone H3R17 methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035642 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to arginine 17 of histone H3, producing S-adenosyl-L-homocysteine and methylated H3R17.
• CARM1 (PRMT4) is the principal enzyme responsible for histone H3R17 methylation, and it preferentially methylates H3R17 over H3R26 through a random kinetic mechanism.
• H3R17 methylation is a chromatin mark associated with transcriptional coactivation and is involved in diverse processes including myogenesis, astroglial lineage specification, autophagy regulation, and gluconeogenesis.
• Small-molecule inhibitors of CARM1-mediated H3R17 methylation have been identified, providing chemical tools to probe the function of this activity.
• Dysregulation of H3R17 methylation has been linked to liver ischemia-reperfusion injury and metabolic control, highlighting its pathophysiological relevance.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of H3R17 methyltransferase activity in disease and development.
Description
Histone H3R17 methyltransferase activity (GO:0035642) is a molecular function that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to the arginine residue at position 17 of histone H3, yielding S-adenosyl-L-homocysteine and methylated H3R17. This post-translational modification is a key epigenetic mark that influences chromatin structure and gene transcription. The primary enzyme responsible for this activity is coactivator-associated arginine methyltransferase 1 (CARM1, also known as PRMT4), which preferentially methylates H3R17 over H3R26 through a random kinetic mechanism. Understanding GO:0035642 is essential for researchers studying transcriptional regulation, epigenetic inheritance, and the molecular basis of diseases ranging from cancer to metabolic disorders. The activity has been implicated in diverse biological contexts, including myogenesis, astroglial lineage commitment, autophagy, and gluconeogenesis. Small-molecule inhibitors targeting CARM1-mediated H3R17 methylation have been developed, offering pharmacological tools to dissect its functions. This article provides a comprehensive overview of the mechanism, key genes, regulatory features, disease associations, and experimental approaches for studying histone H3R17 methyltransferase activity.
histone H3R17 methyltransferase activity At A Glance
| GO ID | GO:0035642 |
|---|---|
| GO term | histone H3R17 methyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone-arginine N-methyltransferase activity (H3-R17 specific); histone-H3R17 methyltransferase activity; histone methylase activity (H3-R17 specific); histone methyltransferase activity (H3-R17 specific) |
| Major function | Catalyzes methyl group transfer from S-adenosyl-L-methionine to histone H3 arginine 17, producing S-adenosyl-L-homocysteine and methylated H3R17 |
| Primary enzyme | CARM1 (PRMT4) |
| Reaction | S-adenosyl-L-methionine + (histone H3)-arginine (position 17) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 17) |
| Substrate | Histone H3 with arginine at position 17 |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor |
What Is GO:0035642?
Histone H3R17 methyltransferase activity (GO:0035642) is defined as the catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 17) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 17). In other words, it is the addition of a methyl group to the arginine residue at position 17 of histone H3. This activity is a type of protein arginine methyltransferase activity with specificity for histone H3 at arginine 17.
Why Is histone H3R17 methyltransferase activity Important in Cell Biology?
Histone H3R17 methyltransferase activity is important because it generates a chromatin mark that regulates gene expression programs central to development, metabolism, and disease. CARM1-mediated H3R17 methylation acts as a transcriptional coactivator mark and is involved in myogenesis, astroglial lineage specification, autophagy, and gluconeogenesis. Dysregulation of this activity has been linked to liver ischemia-reperfusion injury and metabolic disorders, and small-molecule inhibitors of CARM1 have been identified as potential therapeutic leads. Thus, understanding GO:0035642 provides mechanistic insight into epigenetic control and offers opportunities for therapeutic intervention.
• Regulates transcriptional coactivation through deposition of H3R17 methylation, influencing gene expression programs.
• Plays a role in myogenesis, as protein arginine methyltransferase expression and activity change during muscle differentiation.
• Controls astroglial lineage commitment via transcriptional regulation of Nanog and posttranscriptional regulation by miR92a.
• Participates in the epigenetic and transcriptional regulation of autophagy.
• Is involved in metabolic control, including gluconeogenesis, where metformin inhibits CARM1 and attenuates H3 histone methylation.
• Contributes to liver ischemia-reperfusion injury through redox-sensitive epigenetic activation of SUV39H1.
• Can be targeted by small-molecule inhibitors, offering pharmacological tools for research and potential therapy.
• Serves as a model for understanding arginine methylation specificity, as CARM1 preferentially methylates H3R17 over H3R26.
• Provides a paradigm for crosstalk between histone modifications and cellular signaling pathways.
• Is relevant to cancer biology and other diseases where epigenetic dysregulation is a hallmark.
What Happens During histone H3R17 methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme finds and grabs the histone protein at the right spot.
The enzyme CARM1 recognizes histone H3 and binds to it, positioning the arginine 17 residue near the active site. This specificity is achieved through interactions with the histone tail and adjacent residues, allowing CARM1 to preferentially methylate H3R17 over H3R26.
Methyl group transfer
In simple terms: The enzyme takes a methyl group from a donor molecule and attaches it to the target arginine.
Using S-adenosyl-L-methionine (SAM) as the methyl donor, CARM1 transfers a methyl group to the guanidino nitrogen of arginine 17 on histone H3. This reaction produces S-adenosyl-L-homocysteine (SAH) and methylated H3R17. The kinetic mechanism is random, meaning SAM and the histone substrate can bind in either order.
Product formation and release
In simple terms: The modified histone and the byproduct are released.
After methyl transfer, the methylated histone H3 and SAH are released from the enzyme. The newly formed H3R17me mark can then be recognized by reader proteins that interpret the epigenetic signal.
Chromatin remodeling and transcriptional effects
In simple terms: The mark helps open up the DNA for gene activation.
H3R17 methylation serves as a docking site for transcriptional coactivators and chromatin remodelers, leading to increased accessibility of target gene promoters and enhanced transcription. This activity has been linked to the regulation of genes involved in myogenesis, astroglial lineage, autophagy, and gluconeogenesis.
Key Genes Involved in GO:0035642 histone H3R17 methyltransferase activity
The following genes and proteins are directly involved in or regulate histone H3R17 methyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CARM1 (PRMT4) | Primary enzyme catalyzing H3R17 methylation | Central to studies of H3R17 methyltransferase activity; target for inhibitors |
| PRMT1 | Protein arginine methyltransferase; can methylate histones | Contributes to overall histone arginine methylation; potential crosstalk |
| PRMT5 | Protein arginine methyltransferase | May influence global methylation status; context-dependent |
| SUV39H1 | Histone methyltransferase for H3K9 | Linked to redox-sensitive epigenetic activation in liver injury |
| Nrf2 | Transcription factor | Coordinates with PRMT1 and PRMT4 in ferritin gene regulation |
| Nanog | Pluripotency transcription factor | Regulated by CARM1 in astroglial lineage |
| miR92a | MicroRNA | Posttranscriptional regulator in CARM1-dependent astroglial differentiation |
| Metformin | Pharmacological agent | Inhibits CARM1 and attenuates H3 methylation during gluconeogenesis |
| SAM (S-adenosyl-L-methionine) | Methyl donor cofactor | Essential substrate for the methyltransferase reaction |
| SAH (S-adenosyl-L-homocysteine) | Reaction byproduct | Product of methyl transfer; can inhibit methyltransferases |
| H3R17me | Methylated histone mark | Epigenetic mark generated by GO:0035642; read by effector proteins |
| Histone H3 | Substrate protein | Contains the target arginine 17 residue |
| CARM1 inhibitor (e.g., from Selvi et al.) | Small-molecule inhibitor | Chemical tool to probe H3R17 methylation function |
| PRMT4 (alternative name for CARM1) | Enzyme | Same as CARM1; used in early literature |
| Autophagy-related genes | Downstream targets | Regulated by epigenetic and transcriptional mechanisms involving H3R17 methylation |
| Gluconeogenic genes | Downstream targets | Regulated by CARM1 activity and H3 methylation |
How Is histone H3R17 methyltransferase activity Regulated?
Histone H3R17 methyltransferase activity is regulated at multiple levels. The expression and activity of CARM1, the primary enzyme, can be modulated during differentiation processes such as myogenesis. Posttranslational modifications and interaction partners may influence its enzymatic activity. Metformin has been shown to inhibit CARM1 and attenuate H3 histone methylation during gluconeogenesis, indicating pharmacological regulation. Redox-sensitive epigenetic activation of SUV39H1 can also impact the broader chromatin methylation landscape in liver ischemia-reperfusion injury. Additionally, small-molecule inhibitors have been identified that specifically block CARM1-mediated methylation of H3R17, providing a means to regulate this activity experimentally.
histone H3R17 methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CARM1 | Cancer, metabolic disorders | Knockout and overexpression cell models; inhibitor treatment |
| SUV39H1 | Liver ischemia-reperfusion injury | Knockout or point-mutation models in hepatocytes |
| Nanog | Astroglial lineage specification | Knockdown or knockout in neural stem cells |
| miR92a | Neural development | Overexpression or knockout in differentiation models |
| Autophagy genes | Autophagy-related diseases | Knockout models and autophagy flux assays |
Liver ischemia-reperfusion injury
Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury, and this process involves changes in histone methylation including H3R17 methylation. The interplay between oxidative stress and epigenetic modifiers highlights the role of H3R17 methyltransferase activity in tissue damage and repair.
Metabolic disorders and gluconeogenesis
Metformin inhibits the histone methyltransferase CARM1 and attenuates H3 histone methylation during gluconeogenesis, linking H3R17 methylation to metabolic control. Dysregulation of this activity may contribute to hyperglycemia and related metabolic disorders.
Cancer and transcriptional dysregulation
CARM1-mediated H3R17 methylation acts as a transcriptional coactivator mark that can promote oncogenic gene expression programs. Small-molecule inhibitors of CARM1 have been developed, suggesting a potential therapeutic strategy for cancers dependent on this activity.
Developmental and neurological disorders
CARM1 regulates astroglial lineage through transcriptional regulation of Nanog and posttranscriptional regulation by miR92a, implicating H3R17 methylation in neural development. Disruption of this pathway may contribute to neurodevelopmental disorders.
From histone H3R17 methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CARM1 abolish H3R17 methylation? | CARM1 knockout cell line |
| How does a specific point mutation in CARM1 affect substrate specificity? | Point-mutation knock-in of CARM1 |
| Can a disease-associated mutation in histone H3 alter H3R17 methylation? | Histone H3 knock-in with R17 mutation |
| What are the downstream transcriptional effects of H3R17 methylation? | Overexpression of CARM1 followed by RNA-seq |
| How does H3R17 methylation change during differentiation? | Tagged knock-in of CARM1 for ChIP-seq |
| Can small-molecule inhibitors block H3R17 methylation in vivo? | Xenograft or organoid models treated with inhibitors |
How to Study the histone H3R17 methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Protein levels of methylated H3R17 | Detecting changes in global methylation |
| ChIP-seq | Genome-wide localization of H3R17me | Mapping epigenetic marks to target genes |
| In vitro methyltransferase assay | Enzymatic activity and kinetics | Characterizing CARM1 specificity and inhibition |
| RNA-seq | Transcriptional changes | Identifying downstream pathways |
| qRT-PCR | Expression of specific genes | Validating RNA-seq findings |
| Immunofluorescence | Cellular localization of H3R17me | Visualizing epigenetic marks in situ |
| Mass spectrometry | Quantification of histone modifications | Global histone modification profiling |
| CRISPR screening | Identification of genes regulating H3R17 methylation | Functional genomics |
Western blotting and antibodies
Specific antibodies against methylated H3R17 can be used in Western blotting to detect changes in global H3R17 methylation levels upon genetic or pharmacological perturbation.
Chromatin immunoprecipitation (ChIP)
ChIP with anti-H3R17me antibodies followed by sequencing (ChIP-seq) or quantitative PCR allows mapping of H3R17 methylation across the genome and correlation with transcriptional activity.
In vitro methyltransferase assays
Recombinant CARM1 and histone substrates can be used in in vitro assays with radiolabeled SAM to measure methyltransferase activity and kinetics.
RNA sequencing (RNA-seq)
RNA-seq can reveal global transcriptional changes resulting from knockout, knockdown, or overexpression of CARM1, providing insights into downstream pathways regulated by H3R17 methylation.
How CRISPR Can Be Used to Study GO:0035642 histone H3R17 methyltransferase activity
Knockout
CRISPR knockout of CARM1 (PRMT4) can completely abolish H3R17 methyltransferase activity, providing a clean background to study its loss-of-function phenotypes in processes such as myogenesis, autophagy, and gluconeogenesis.
Point Mutation
Introducing point mutations in the catalytic domain of CARM1 or in the histone H3 arginine 17 residue can dissect the specific contribution of H3R17 methylation versus other functions. For example, mutating H3R17 to a non-methylatable residue prevents the mark.
Knock-in
Knock-in of tagged CARM1 (e.g., FLAG or HA) allows for affinity purification and ChIP-seq studies to map H3R17 methylation sites and identify interacting partners.
Overexpression
Overexpression of wild-type or mutant CARM1 can elevate H3R17 methylation levels, enabling gain-of-function studies to assess downstream transcriptional and phenotypic effects.
How EDITGENE Supports histone H3R17 methyltransferase activity Research
Researchers studying histone H3R17 methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in the deposition or regulation of this epigenetic mark. Precise genetic models are essential to link specific genes to H3R17 methylation and its downstream biological consequences.
Contact EDITGENE today to design your custom CRISPR model for histone H3R17 methyltransferase activity research.
Frequently Asked Questions About histone H3R17 methyltransferase activity
What is histone H3R17 methyltransferase activity?
It is the enzymatic activity that adds a methyl group to arginine 17 of histone H3, using S-adenosyl-L-methionine as the methyl donor, as defined by GO:0035642.
What genes are involved in histone H3R17 methyltransferase activity?
The primary gene is CARM1 (PRMT4), which encodes the enzyme responsible for this activity. Other PRMTs such as PRMT1 may also contribute to histone arginine methylation.
Which enzyme catalyzes H3R17 methylation?
CARM1 (coactivator-associated arginine methyltransferase 1, also known as PRMT4) is the principal enzyme that catalyzes H3R17 methylation.
What is the role of H3R17 methylation in gene expression?
H3R17 methylation acts as a transcriptional coactivator mark that promotes chromatin accessibility and gene activation, influencing processes like myogenesis, astroglial differentiation, and autophagy.
How is H3R17 methyltransferase activity regulated?
It is regulated by CARM1 expression levels, posttranslational modifications, interaction partners, and pharmacological agents such as metformin, which inhibits CARM1.
What diseases are associated with H3R17 methylation?
Dysregulation has been linked to liver ischemia-reperfusion injury, metabolic disorders, cancer, and developmental disorders.
Can H3R17 methylation be inhibited?
Yes, small-molecule inhibitors of CARM1-mediated H3R17 methylation have been identified, providing chemical tools for research and potential therapeutic leads.
What methods are used to study H3R17 methyltransferase activity?
Common methods include Western blotting with anti-H3R17me antibodies, ChIP-seq, in vitro methyltransferase assays, and RNA-seq.
What is the difference between H3R17 and H3R26 methylation?
CARM1 preferentially methylates H3R17 over H3R26, and the two marks can have distinct transcriptional outcomes.
How can CRISPR be used to study H3R17 methylation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of CARM1 and histone H3 to dissect the function of H3R17 methylation.
Conclusion
Histone H3R17 methyltransferase activity (GO:0035642) is a key epigenetic function primarily mediated by CARM1, with important roles in transcriptional regulation, development, metabolism, and disease. Understanding its mechanism, regulation, and downstream effects provides insights into fundamental biology and potential therapeutic targets. CRISPR-based models and advanced methodologies continue to illuminate the precise functions of this activity in health and disease.
References
- 1. Li Z et al.. 2024. Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury.. Redox Biol 78:103414 PMID: 39603205
- 2. Dhang S et al.. 2025. Metformin inhibits the histone methyltransferase CARM1 and attenuates H3 histone methylation during gluconeogenesis.. J Biol Chem 301(3):108271 PMID: 39922487
- 3. Shen NY et al.. 2018. Protein arginine methyltransferase expression and activity during myogenesis.. Biosci Rep 38(1) PMID: 29208765
- 4. Huang BW et al.. 2013. Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4.. FASEB J 27(9):3763-74 PMID: 23699174
- 5. Selvi BR et al.. 2015. CARM1 regulates astroglial lineage through transcriptional regulation of Nanog and posttranscriptional regulation by miR92a.. Mol Biol Cell 26(2):316-26 PMID: 25392304
- 6. Shin HR et al.. 2016. Epigenetic and transcriptional regulation of autophagy.. Autophagy 12(11):2248-2249 PMID: 27487449
- 7. Jacques SL et al.. 2016. CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism.. Biochemistry 55(11):1635-44 PMID: 26848779
- 8. Selvi BR et al.. 2010. Identification of a novel inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1)-mediated methylation of histone H3 Arg-17.. J Biol Chem 285(10):7143-52 PMID: 20022955
